Cardiovascular Pharmacogenomics

2011/09/16 by Dan M. Roden, Julie A. Johnson, Stephen E. Kimmel +6 · 26 citations
Pharmacology, Toxicology and Pharmaceutics · Medicine · #Pharmacogenetics and Drug Metabolism #Antiplatelet Therapy and Cardiovascular Diseases #Pharmacology and Obesity Treatment

paper · pdf · doi:10.1161/circresaha.110.230995

Abstract

Patients vary in their responses to drug therapy, and some of that variability is genetically determined. This review outlines general approaches used to identify genetic variation that influences drug response. Examples from specific therapeutic areas are presented, such as cholesterol management, arrhythmias, heart failure, hypertension, warfarin anticoagulation, and antiplatelet agents. A brief view of potential pathways to implementation is presented.

Cited by

• Pharmacogenetics and Cardiovascular Disease—Implications for Personalized Medicine
• Pharmacogenomics: application to the management of cardiovascular disease. [europepmc]
• Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. [europepmc]
• Genetic determinants of response to cardiovascular drugs. [europepmc]
• Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. [europepmc]
• Genetic background influences adaptation to cardiac hypertrophy and Ca(2+) handling gene expression. [europepmc]
• Characterization of statin dose response in electronic medical records. [europepmc]
• Pharmacogenetics of heart failure. [europepmc]
• Personalized medicine to treat arrhythmias. [europepmc]
• Towards a molecular systems model of coronary artery disease. [europepmc]
• Biopsychosocial influence on shoulder pain: risk subgroups translated across preclinical and clinical prospective cohorts. [europepmc]
• Common variants of the G protein-coupled receptor type 4 are associated with human essential hypertension and predict the blood pressure response to angiotensin receptor blockade. [europepmc]
• Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs. [europepmc]
• Cardiovascular pharmacogenomics: current status and future directions. [europepmc]
• Moving From Digitalization to Digitization in Cardiovascular Care: Why Is it Important, and What Could it Mean for Patients and Providers? [europepmc]
• Personalized medicine in thrombosis: back to the future. [europepmc]
• Pharmacogenetics of Potassium Channel Blockers. [europepmc]
• Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial. [europepmc]
• Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. [europepmc]
• Pharmacogenetics in Cardiovascular Medicine. [europepmc]
• Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation. [europepmc]
• Genetic variations in the transcription factors GATA4 and GATA6 and bleeding complications in patients receiving warfarin therapy. [europepmc]
• Effects of Polymorphisms in Myc-Related Genes on Bleeding Complications in Patients with Stable Warfarin Responses. [europepmc]
• Variants in CDHR3, CACNAC1 , and LTA Genes Predisposing Sensitivity and Response to Warfarin in Patients with Cardiovascular Disease. [europepmc]
• Biopsychosocial influence on shoulder pain: results from a randomized preclinical trial of exercise-induced muscle injury. [europepmc]
• Individualized Dose-Response to Statins Associated with Cardiovascular Disease Outcomes. [europepmc]

Related

• Characterizing the genetic architecture of drug response using gene-context interaction methods
• Pharmacogenomics Knowledge for Personalized Medicine
• Pharmacogenetics and drug metabolism - from rudiments to current for individualised medicine
• Pharmacogenomics: Driving Personalized Medicine
• Investigating the genetic factors of medication dosing using biobank-linked drug purchase data